Advertisement

Table of Contents

May 01, 2023; Volume 103,Issue 5

Minireview

You have access
Aryl Hydrocarbon Receptor as a Therapeutical Target of Environmentally Induced Skin Conditions
Caroline de Almeida Freitas Accioli, Michelle Sabrina da Silva, Bianca Aloise Maneira Corrêa Santos and Carlos Rangel Rodrigues

Molecular Pharmacology May 2023, 103 (5) 255-265; DOI: https://doi.org/10.1124/molpharm.122.000627

Articles

You have access
Alkannin Attenuates Amyloid β Aggregation and Alzheimer’s Disease Pathology
Toru Hosoi, Kyosuke Yazawa, Michihiro Imada, Akari Tawara, Chihiro Tohda, Yasuyuki Nomura and Koichiro Ozawa

Molecular Pharmacology May 2023, 103 (5) 266-273; DOI: https://doi.org/10.1124/molpharm.121.000468
You have access
Application of Mixed-Solvent Molecular Dynamics Simulations for Prediction of Allosteric Sites on G Protein–Coupled Receptors
Wallace K.B. Chan, Heather A. Carlson and John R. Traynor

Molecular Pharmacology May 2023, 103 (5) 274-285; DOI: https://doi.org/10.1124/molpharm.122.000612
You have access
BAY58-2667 Activates Different Soluble Guanylyl Cyclase Species by Distinct Mechanisms that Indicate Its Principal Target in Cells is the Heme-Free Soluble Guanylyl Cyclase-Heat Shock Protein 90 Complex
Yue Dai and Dennis J. Stuehr

Molecular Pharmacology May 2023, 103 (5) 286-296; DOI: https://doi.org/10.1124/molpharm.122.000624

Erratum

You have access
Correction to “A Novel Semisynthetic Inhibitor of the FRB Domain of Mammalian Target of Rapamycin Blocks Proliferation and Triggers Apoptosis in Chemoresistant Prostate Cancer Cells”
Molecular Pharmacology May 2023, 103 (5) 297; DOI: https://doi.org/10.1124/mol.112.081349err
You have access
Correction to “The Common LncRNAs of Neuroinflammation-Related Diseases”
Molecular Pharmacology May 2023, 103 (5) 298; DOI: https://doi.org/10.1124/molpharm.122.000530err